Compare AbCellera Biologics Inc (ABCL) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs ProShares Ultra QQQ ETF — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while ProShares Ultra QQQ ETF trades at $89.24. Which is the better fit depends on your goals.
| ABCL | QLD | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $8.12 | $100.53 |
52-Week Low | $2.78 | $57.16 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
QLD, the ProShares Ultra QQQ ETF, trades at $93.12, up 2.8% today, reflecting strong bullish momentum with a technical buy signal from moving averages. As a 2x leveraged ETF tracking the Nasdaq-100, it amplifies returns but carries inherent volatility risks. Recent news highlights its long-term performance, with over 10,000% total return since inception, though it experienced significant drawdowns historically.
The outlook for QLD is tied to tech sector strength, with AI optimism and easing geopolitical tensions supporting growth. However, leveraged ETFs like QLD are high-risk tactical instruments unsuitable for long-term holdings due to daily rebalancing effects. Investors should weigh potential amplified gains against the risk of sharp declines in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
